EyePoint
EyePoint's revenue fell 27.5% to $31 million in fiscal 2025. Its operating margin was −776.0%, down from −337.1% a year earlier. Free cash flow was −$243 million. The diluted share count rose 30.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What EyePoint does
EyePoint is a clinical-stage biopharmaceutical company, meaning its drug candidates are still being tested and none of its pipeline products is approved. It works on treatments for serious retinal diseases, using its Durasert E technology, a tiny dissolving insert that releases a drug inside the eye over time and is placed with a standard injection in a doctor's office.
Its main product candidate, DURAVYU, combines a drug called vorolanib with that technology to treat diseases driven by a protein called VEGF. It is in Phase 3 trials for wet age-related macular degeneration, and in Phase 3 trials for diabetic macular edema. Enrollment in the wet AMD trials is complete, with data expected beginning in mid-2026. Its other programs include EYP-2301 and razuprotafib.
The company is based in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. It sold the eye product DEXYCU from 2019 to 2023.
Its biggest risks, as it describes them
- Needing more money, which could force it to cut back its operations.
- Losses since its start and no assurance it will ever be profitable.
- Relying heavily on one candidate, DURAVYU, which is still in trials.
- Clinical trials that are delayed, fail or give results that later change.
- A 2022 subpoena from the U.S. Attorney's Office about sales and marketing practices for DEXYCU.
Income statement
EyePoint lost money in fiscal 2025: a net loss of $232 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 212 | 145 | 331 | 371 | 306 |
| Debt incl. finance leases | 37 | 40 | — | — | — |
| Net debt (negative means net cash) | −175 | −104 | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | 0.4x | — | — | — |
| Interest coverage | −10.1x | −31.2x | −60.2x | −10,418.1x | −7,376.8x |
| Current ratio | 10.1x | 5.0x | 5.5x | 7.8x | 8.9x |
| Quick ratio | 9.9x | 4.9x | 5.4x | 7.8x | 8.8x |
Cash flow
Projections
Project EyePoint's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What EyePoint says to expect
- Cash runway
We expect the cash, cash equivalents, and marketable securities as of September 30, 2026, together with the additional $10 million of capital raised subsequent to quarter-end pursuant to our “at-the-market” equity facility and with anticipated operational adjustments, will enable us to fund operations into late third quarter of 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $71,983 of EyePoint shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Karen L. ZaderejDirector | Bought | 10,600 | $4.93 | $52,258 | Form 4 |
| Mar 16, 2026 | Jay S. DukerPresident and CEO, Director | Bought | 1,500 | $13.15 | $19,725 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 7.7% | −307.0% | −803.4% |
| Altman Z'' | 0.11 | 0.41 | −3.58 |
| Accruals ratio | −27.1% | −1.2% | 2.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put EyePoint side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| EyePoint | FY25 | −27.5% | −776.0% | −775.8% | — | — | — | |
| Foghorn Therapeutics | FY25 | 36.8% | −279.5% | −278.7% | — | — | 2 | Compare |
| Verastem | FY25 | 209.1% | −550.3% | — | — | — | — | Compare |
| Scilex | FY25 | −46.5% | −1,143.7% | 12.2% | — | — | 3 | Compare |
| Nanobiotix | FY25 | — | −33.2% | −104.2% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 8 | 3 | 20 | 34 | 37 | 41 | 46 | 43 | 31 |
| Revenue growth | −93.9% | 365.4% | −60.7% | 587.8% | 69.1% | 7.3% | 12.1% | 11.1% | −6.0% | −27.5% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 14 | 15 | 16 | 15 | 17 | 28 | 50 | 65 | 133 | 221 |
| Operating income | −22 | −19 | −26 | −48 | −37 | −55 | −100 | −75 | −146 | −243 |
| Net income | −22 | −18 | −53 | −57 | −45 | −58 | −102 | −71 | −131 | −232 |
| Diluted EPS (US$) | −6.80 | −5.20 | −11.50 | −5.44 | −3.54 | −2.03 | −2.74 | −1.82 | −2.32 | −3.17 |
| Diluted shares (millions) | 3 | 4 | 5 | 10 | 13 | 29 | 37 | 39 | 56 | 73 |
| Cash flow | ||||||||||
| Cash from operations | −16 | −20 | −22 | −57 | −14 | −50 | −65 | 2 | −126 | −240 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 4 | 3 |
| Free cash flow | −16 | −21 | −22 | −57 | −15 | −50 | −67 | −2 | −130 | −243 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 3 | 5 | 6 | 7 | 14 | 12 | 37 | 28 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 29 | — | 39 | 22 | 45 | 212 | 145 | 331 | 371 | 306 |
| Debt incl. finance leases | — | 0 | 17 | 47 | 38 | 37 | 40 | — | — | — |
| Total assets | 32 | 19 | 72 | 73 | 92 | 263 | 180 | 355 | 418 | 364 |
| Total liabilities | 11 | 5 | 60 | 65 | 73 | 79 | 84 | 89 | 82 | 58 |
| Shareholders' equity | 21 | 13 | 12 | 8 | 18 | 184 | 96 | 266 | 336 | 306 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −1,344.1% | −246.4% | −887.3% | −235.0% | −108.3% | −149.6% | −240.7% | −163.1% | −337.1% | −776.0% |
| Net margin | −1,330.1% | −245.2% | −1,795.7% | −278.9% | −131.8% | −158.1% | −247.0% | −153.8% | −302.4% | −739.4% |
| Free cash flow margin | −1,014.1% | −273.7% | −743.5% | −279.5% | −43.0% | −136.0% | −162.2% | −3.5% | −301.1% | −775.8% |
| Rule of 40 (growth + FCF margin) | −1,108.0% | 91.6% | −804.2% | 308.3% | 26.1% | −128.8% | −150.1% | 7.7% | −307.0% | −803.4% |
| Return on capital | — | — | — | −321.0% | −130.5% | — | — | — | — | — |
| Return on equity | −97.4% | −108.0% | −425.0% | −567.5% | −337.9% | −57.6% | −72.8% | −39.0% | −43.4% | −72.2% |
| Return on assets | −67.3% | −73.5% | −117.7% | −78.5% | −55.1% | −32.9% | −46.1% | −26.4% | −33.8% | −59.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |